US5165441032 - Common Stock
LANTHEUS HOLDINGS INC
NASDAQ:LNTH (4/25/2024, 7:02:54 PM)
After market: 65.2 0 (0%)65.2
-0.01 (-0.02%)
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 698 full-time employees. The company went IPO on 2015-06-25. The firm's products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company's license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
LANTHEUS HOLDINGS INC
331 Treble Cove Rd
North Billerica MASSACHUSETTS 01862
P: 19786718001
CEO: Mary Anne Heino
Employees: 698
Website: https://www.lantheus.com/
In the world of growth stocks, LANTHEUS HOLDINGS INC (NASDAQ:LNTH) shines as a value proposition.
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference...
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) qualifies as a high growth stock and is consolidating.
You might not have heard of these stocks, but they're worth putting on your radar.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH), an undervalued stock with good fundamentals.
Here you can normally see the latest stock twits on LNTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: